Alexis Te, MD, is Professor of Urology at the Icahn School of Medicine at Mount Sinai, where he is Co-Director of the Men's Health Program and Director of the Advanced Center for Benign Prostatic Diseases.
He completed his Bachelor of Science in Molecular Biophysics and Biochemistry at Yale University and received his MD from Weill Medical College at Cornell University. His postgraduate training includes a urology residency at Columbia-Presbyterian Medical Center and a fellowship in neurourology and urodynamics at the College of Physicians and Surgeons at Columbia University.
Dr. Te has published more than 170 peer-reviewed articles focusing on benign prostatic disorders and incontinence treatment. His research covers benign prostatic hyperplasia (BPH), BPH therapies, incontinence, prostatitis, neurourology, urodynamics, female urology, interstitial cystitis, laser surgery, and prostate cancer.
He is a member of several professional organizations and holds editorial positions in numerous journals. He has been recognized in Super Docs, Castle Connolly: Best Doctor in NY Metro Area–Urology, the Best Doctors in America database, and on the New York magazine Best Doctors list. Dr. Te was Director of the Brady Urologic Health Center at Weill Cornell Medicine from 2000 through 2023, and a Consultant at NewYork-Presbyterian Hospital beginning in 2002. He was Director of the Urology Program at the Iris Cantor Men’s Health Center of NewYork-Presbyterian/Weill Cornell Medical Center from 2012 until 2023 and the Urodynamic Laboratory from 2000 to 2023.
Selected publications from PubMed
Editorial Comment on "A Practical Phenotyping Framework for Male Lower Urinary Tract Symptoms Using Remote Multi-day Urinary Diagnostics".
Te AE
Urology. 2026 May;211:100-101 doi: 10.1016/j.urology.2026.03.028.
ChatGPT Health performance in a structured test of triage recommendations.
Ramaswamy A, Tyagi A, Hugo H, Jiang J, Jayaraman P, Jangda M, Te AE, Kaplan SA, Lampert J, Freeman R, Gavin N, Tewari AK, Sakhuja A, Naved B, Charney AW, Omar M, Gorin MA, Klang E, Nadkarni GN
Nat Med. 2026 May;32(5):1671-1675 doi: 10.1038/s41591-026-04297-7.
12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.
Kaplan SA, Parekattil SJ, Wu NZ, Mazzarella B, Trotter M, Freedman S, Lawindy S, Bukkapatnam R, Schwartz BF, Jones B, Sethi P, Jalkut M, Liu JS, Elterman D, Gheiler E, Gonzalez RR, Kaminetsky J, Motola JA, Te A, Chapple C, Lerner L, Lynch T
J Urol. 2026 Apr;215(4):421-430 doi: 10.1097/JU.0000000000004896.
Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms.
Te AE, Ramaswamy A, Kaplan SA
Urol Clin North Am. 2025 Nov;52(4):595-604 doi: 10.1016/j.ucl.2025.08.001.
Balloons in Benign Prostatic Hyperplasia: Will They Float? A Comprehensive Review of Prostatic Balloon Prostatoplasty.
Te AE, Kaplan SA
Urol Clin North Am. 2025 Nov;52(4):559-566 doi: 10.1016/j.ucl.2025.07.007.
Help your network discover Dr. Alexis Te's clinical expertise.
